艾美疫苗mRNA带状疱疹疫苗临床试验已在美国申报
2月23日，艾美疫苗（06660）发布公告，告知股东及潜在投资者其最新业务进展。公司利用mRNA技术平台的优势，积极推进疫苗产品的研发。最近，公司向美国食品和药品监督管理局(FDA)申报了mRNA带状疱疹疫苗的临床试验，标志着其全球化战略取得新进展。临床前动物试验显示，该疫苗的特异性T细胞免疫、特异性IgG抗体滴度及膜抗原荧光抗体(FAMA)滴度均显著高于国际市售的重组亚单位对照疫苗。
目前国际上尚无mRNA带状疱疹疫苗获批上市，带状疱疹疫苗在目标人群中的接种率仅为0.1%左右，市场潜力巨大。2024年度，GSK的带状疱疹疫苗全球销售额约为43.1亿美元。根据行业顾问灼识咨询的预测，到2030年，带状疱疹疫苗在中国的市场规模将达到约200亿元，全球市场规模将达到约239亿美元。公司预计，该产品获批上市后将带来可观的业绩增长，并有望重塑市场格局。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10